On August 28, 2024 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported that the company will present a company overview at the following conferences (Press release, PTC Therapeutics, AUG 28, 2024, View Source [SID1234646163]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 22nd Annual Global Healthcare Conference
Thursday, Sept. 5 at 9:15 am ET

2024 Wells Fargo Healthcare Conference
Friday, Sept. 6 at 12:00 pm ET

Cantor 2024 Global Healthcare Conference
Tuesday, Sept. 17 at 2:30 pm ET

The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics’ website at View Source and will be archived for 30 days following the presentation. It is recommended that users connect to PTC’s website several minutes prior to the start of the webcast to ensure a timely connection.

On August 28, 2024 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at two upcoming investor conferences in September (Press release, Neurocrine Biosciences, AUG 28, 2024, View Source [SID1234646162]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Executive Officer Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano, and Chief Financial Officer Matt Abernethy will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York at 3:20 p.m. Eastern Time on Wednesday, September 4, 2024.

Kyle Gano and Matt Abernethy will present at the 2024 Wells Fargo Healthcare Conference in Boston at 8:45 a.m. Eastern Time on Thursday, September 5, 2024.

The live presentations will be webcast and may be accessed on Neurocrine Biosciences’ website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

On August 28, 2024 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, reported that members of its senior management team will present and participate in the following upcoming investor conferences (Press release, Lyell Immunopharma, AUG 28, 2024, View Source [SID1234646161]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th at 10:45 am Eastern Time
H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9th at 8:30 am Eastern Time

A live webcast of the presentation can be accessed through the Investors section of the Company’s website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company’s website following the presentation date.

On August 28, 2024 Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, reported that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences (Press release, Keros Therapeutics, AUG 28, 2024, View Source [SID1234646160]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 22nd Annual Global Healthcare Conference

•Date and Time: Wednesday, September 4, 2024 at 4:05 p.m. Eastern time
•Link: View Source
•Format: Fireside Chat Presentation

2024 Wells Fargo Healthcare Conference

•Date and Time: Thursday, September 5, 2024 at 10:15 a.m. Eastern time
•Link: View Source
•Format: Fireside Chat Presentation

2024 Cantor Global Healthcare Conference

•Date and Time: Thursday, September 19, 2024 at 8:35 a.m. Eastern Time
•Link: View Source
•Format: Fireside Chat Presentation

For each presentation, an archived replay will be accessible in the Investors section of the Keros website at View Source for up to 90 days following the conclusion of each event.

On August 28, 2024 IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, reported its investors to mark their calendars for its R&D Day event to be held at the Harvard Club in New York City on September 18th from 10:00 a.m. to 1:00 p.m. Eastern time (Press release, IMUNON, AUG 28, 2024, View Source [SID1234646159]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D Day event follows Imunon’s announcement of top-line data from its randomized Phase II Ovation 2 Study. These data suggest an 11.1 month increase in median OS in the intent-to-treat population, indicating a remarkable 35% improvement in survival among patients with advanced ovarian cancer.

The program will feature ovarian cancer thought leaders, principal investigators from the Company’s Phase 2 OVATION 2 Study of IMNN-001, a review of the study’s topline results and how the data will inform the Phase 3 registration study, and a discussion about the potential role of IMNN-001 in the treatment of advanced ovarian cancer. In addition, management will discuss next steps with its powerful immunotherapy and the prospects for extending patient survival.

We strongly encourage in-person attendance to facilitate networking and direct engagement with our speakers and management team. However, for those unable to attend in person, a virtual participation option will also be available.

Program details including speakers will be upcoming, along with an opportunity to RSVP for participation.